Classical biomarkers of (1) infection (blood leucocytes, PCT), (2) systemic inflammation response (CRP), and (3) organ failure (lactate), as well as new sepsis biomarkers [e.g., interleukin (IL)-6, presepsin, pancreatic stone protein (PSP), mid regional pro-adrenomedullin (MR-proADM), and others] should therefore be studied or re-studied by using the standardized approach proposed above, and this should be done in order to determine the biomarker(s) that address clinicians’ questions, and to identify the four cut-offs for the five level risks (Table 4). The gene discussed is REG1A; the disease is Sepsis.